EUVIMEDEUVIMED entdecken
Open Access

Medicare Part D Payments for Generic Imatinib From 2017 to 2023

Stacie B Dusetzina

JAMA Internal Medicine · 2024

DOI: 10.1001/jamainternmed.2023.3932 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Internal Medicine, 2024. Verfasst von Stacie B Dusetzina. Beteiligte Einrichtung: Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee. Hauptthemen laut MEDLINE: Medicare Part D, Prescription Drugs. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This cross-sectional study compares pharmacy acquisition costs and point-of-sale prices for generic imatinib under Medicare Part D from 2017 to 2023.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medicare Part DPrescription DrugsAgedHumansUnited StatesImatinib MesylateDrug SubstitutionDrugs, GenericDrug Costs

Substanzen

Imatinib MesylatePrescription DrugsDrugs, Generic

Autor:innen und Institutionen

  • Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.
  • Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

Zitieren

APA

Dusetzina, S. B. (2024). Medicare Part D Payments for Generic Imatinib From 2017 to 2023. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2023.3932

Vancouver

Dusetzina SB. Medicare Part D Payments for Generic Imatinib From 2017 to 2023. JAMA Internal Medicine. 2024. doi:10.1001/jamainternmed.2023.3932

BibTeX
@article{Dusetzina2024,
  author = {Dusetzina, Stacie B},
  title = {Medicare Part D Payments for Generic Imatinib From 2017 to 2023},
  journal = {JAMA Internal Medicine},
  year = {2024},
  doi = {10.1001/jamainternmed.2023.3932}
}
Kostenlos starten →